Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru

D. G. Apaza Veliz; R. D. Herrera Vera; C. A. Cardenas Abarca; C. A. Oporto Gonzales; C. Aguilar Ramírez; Jose Luis Javier Vega  Ramirez; R. M. Urquizo Baldomero

doi:10.1063/1.4955384

Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru

D. G. Apaza Veliz, R. D. Herrera Vera, C. A. Cardenas Abarca, C. A. Oporto Gonzales, C. Aguilar Ramírez, Jose Luis Javier Vega Ramirez, R. M. Urquizo Baldomero

Departamento Académico de Física

Resultado de la investigación: Capítulo del libro/informe/acta de congreso › Contribución a la conferencia › revisión exhaustiva

Resumen

The Iodine-131 (I-131) is a radioisotope used as a standard treatment for radioablation of thyroid remnants. Among thyroid cancer patients, the ones undergoing hemodialysis represent a specific group. The dose of I-131 is given orally to these patients, part of it is absorbed by the thyroid remnants and the rest of it, largely not incorporated, is excreted primarily by renal excretion. The use of a high dose of radioactivity in the process, and the inability of excretion, represents a high risk of exposure to the patient, medical staff and hemodialysis equipment. This work describes the procedure applied on the radioablation therapy for thyroid cancer while receiving hemodialysis, minimizing the risks for the patient and the staff involved. This clinical procedure will establish the dosimetric measures, a plan on radiation protection and a treatment protocol for this specific type of patients.

Idioma original	Inglés
Título de la publicación alojada	Latin American Symposium on Nuclear Physics and Applications, LASNPA 2015
Editores	Fernando Cristancho
Editorial	American Institute of Physics Inc.
ISBN (versión digital)	9780735414112
DOI	https://doi.org/10.1063/1.4955384
Estado	Publicada - 7 jul. 2016
Evento	11th Latin American Symposium on Nuclear Physics and Applications, LASNPA 2015 - Medellin, Colombia Duración: 30 nov. 2015 → 4 dic. 2015

Serie de la publicación

Nombre	AIP Conference Proceedings
Volumen	1753
ISSN (versión impresa)	0094-243X
ISSN (versión digital)	1551-7616

Conferencia

Conferencia	11th Latin American Symposium on Nuclear Physics and Applications, LASNPA 2015
País/Territorio	Colombia
Ciudad	Medellin
Período	30/11/15 → 4/12/15

Nota bibliográfica

Publisher Copyright:
© 2016 Author(s).

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1063/1.4955384

Otros archivos y enlaces

Enlace a la publicación en Scopus

Citar esto

Apaza Veliz, D. G., Herrera Vera, R. D., Cardenas Abarca, C. A., Oporto Gonzales, C. A., Aguilar Ramírez, C., Vega Ramirez, J. L. J., & Urquizo Baldomero, R. M. (2016). Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru. En F. Cristancho (Ed.), Latin American Symposium on Nuclear Physics and Applications, LASNPA 2015 [080014] (AIP Conference Proceedings; Vol. 1753). American Institute of Physics Inc.. https://doi.org/10.1063/1.4955384

Apaza Veliz, D. G. ; Herrera Vera, R. D. ; Cardenas Abarca, C. A. et al. / Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru. Latin American Symposium on Nuclear Physics and Applications, LASNPA 2015. editor / Fernando Cristancho. American Institute of Physics Inc., 2016. (AIP Conference Proceedings).

@inproceedings{0cc9d508a8704e2b9d400ea70051f38d,

title = "Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru",

abstract = "The Iodine-131 (I-131) is a radioisotope used as a standard treatment for radioablation of thyroid remnants. Among thyroid cancer patients, the ones undergoing hemodialysis represent a specific group. The dose of I-131 is given orally to these patients, part of it is absorbed by the thyroid remnants and the rest of it, largely not incorporated, is excreted primarily by renal excretion. The use of a high dose of radioactivity in the process, and the inability of excretion, represents a high risk of exposure to the patient, medical staff and hemodialysis equipment. This work describes the procedure applied on the radioablation therapy for thyroid cancer while receiving hemodialysis, minimizing the risks for the patient and the staff involved. This clinical procedure will establish the dosimetric measures, a plan on radiation protection and a treatment protocol for this specific type of patients.",

keywords = "Dosimetry, Hemodialysis, Iodine-131, Radioablative Therapy, Radiology Protection",

author = "{Apaza Veliz}, {D. G.} and {Herrera Vera}, {R. D.} and {Cardenas Abarca}, {C. A.} and {Oporto Gonzales}, {C. A.} and {Aguilar Ram{\'i}rez}, C. and {Vega Ramirez}, {Jose Luis Javier} and {Urquizo Baldomero}, {R. M.}",

note = "Publisher Copyright: {\textcopyright} 2016 Author(s).; null ; Conference date: 30-11-2015 Through 04-12-2015",

year = "2016",

month = jul,

day = "7",

doi = "10.1063/1.4955384",

language = "Ingl{\'e}s",

series = "AIP Conference Proceedings",

publisher = "American Institute of Physics Inc.",

editor = "Fernando Cristancho",

booktitle = "Latin American Symposium on Nuclear Physics and Applications, LASNPA 2015",

}

Apaza Veliz, DG, Herrera Vera, RD, Cardenas Abarca, CA, Oporto Gonzales, CA, Aguilar Ramírez, C, Vega Ramirez, JLJ & Urquizo Baldomero, RM 2016, Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru. En F Cristancho (ed.), Latin American Symposium on Nuclear Physics and Applications, LASNPA 2015., 080014, AIP Conference Proceedings, vol. 1753, American Institute of Physics Inc., 11th Latin American Symposium on Nuclear Physics and Applications, LASNPA 2015, Medellin, Colombia, 30/11/15. https://doi.org/10.1063/1.4955384

Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru. / Apaza Veliz, D. G.; Herrera Vera, R. D.; Cardenas Abarca, C. A. et al.

Latin American Symposium on Nuclear Physics and Applications, LASNPA 2015. ed. / Fernando Cristancho. American Institute of Physics Inc., 2016. 080014 (AIP Conference Proceedings; Vol. 1753).

Resultado de la investigación: Capítulo del libro/informe/acta de congreso › Contribución a la conferencia › revisión exhaustiva

TY - GEN

T1 - Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru

AU - Apaza Veliz, D. G.

AU - Herrera Vera, R. D.

AU - Cardenas Abarca, C. A.

AU - Oporto Gonzales, C. A.

AU - Aguilar Ramírez, C.

AU - Vega Ramirez, Jose Luis Javier

AU - Urquizo Baldomero, R. M.

PY - 2016/7/7

Y1 - 2016/7/7

N2 - The Iodine-131 (I-131) is a radioisotope used as a standard treatment for radioablation of thyroid remnants. Among thyroid cancer patients, the ones undergoing hemodialysis represent a specific group. The dose of I-131 is given orally to these patients, part of it is absorbed by the thyroid remnants and the rest of it, largely not incorporated, is excreted primarily by renal excretion. The use of a high dose of radioactivity in the process, and the inability of excretion, represents a high risk of exposure to the patient, medical staff and hemodialysis equipment. This work describes the procedure applied on the radioablation therapy for thyroid cancer while receiving hemodialysis, minimizing the risks for the patient and the staff involved. This clinical procedure will establish the dosimetric measures, a plan on radiation protection and a treatment protocol for this specific type of patients.

AB - The Iodine-131 (I-131) is a radioisotope used as a standard treatment for radioablation of thyroid remnants. Among thyroid cancer patients, the ones undergoing hemodialysis represent a specific group. The dose of I-131 is given orally to these patients, part of it is absorbed by the thyroid remnants and the rest of it, largely not incorporated, is excreted primarily by renal excretion. The use of a high dose of radioactivity in the process, and the inability of excretion, represents a high risk of exposure to the patient, medical staff and hemodialysis equipment. This work describes the procedure applied on the radioablation therapy for thyroid cancer while receiving hemodialysis, minimizing the risks for the patient and the staff involved. This clinical procedure will establish the dosimetric measures, a plan on radiation protection and a treatment protocol for this specific type of patients.

KW - Dosimetry

KW - Hemodialysis

KW - Iodine-131

KW - Radioablative Therapy

KW - Radiology Protection

UR - http://www.scopus.com/inward/record.url?scp=84984559444&partnerID=8YFLogxK

U2 - 10.1063/1.4955384

DO - 10.1063/1.4955384

M3 - Contribución a la conferencia

AN - SCOPUS:84984559444

T3 - AIP Conference Proceedings

BT - Latin American Symposium on Nuclear Physics and Applications, LASNPA 2015

A2 - Cristancho, Fernando

PB - American Institute of Physics Inc.

Y2 - 30 November 2015 through 4 December 2015

ER -

Apaza Veliz DG, Herrera Vera RD, Cardenas Abarca CA, Oporto Gonzales CA, Aguilar Ramírez C, Vega Ramirez JLJ et al. Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru. En Cristancho F, editor, Latin American Symposium on Nuclear Physics and Applications, LASNPA 2015. American Institute of Physics Inc. 2016. 080014. (AIP Conference Proceedings). doi: 10.1063/1.4955384

Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru

Resumen

Serie de la publicación

Conferencia

Nota bibliográfica

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto